By Counterforce Health Team in Eylea / Lucentis (aflibercept / ranibizumab) —

Myths vs. Facts: Getting Eylea and Lucentis Covered by UnitedHealthcare in New Jersey

Quick Answer: UnitedHealthcare requires prior authorization for Eylea and Lucentis in New Jersey, with step therapy typically mandating bevacizumab failure first. If denied, you have 180 days for internal appeals, then can file for external review through New Jersey's IHCAP program administered by Maximus Federal Services. Start by having your doctor submit PA documentation via the UHC Provider Portal with clinical records showing medical necessity.

Table of Contents

Why These Myths Persist

When you're facing vision loss from wet AMD or diabetic macular edema, it's natural to assume your doctor's prescription for Eylea or Lucentis will be automatically covered. Unfortunately, the reality of specialty drug coverage is far more complex than most patients realize.

These myths persist because insurance companies don't always clearly communicate their requirements upfront, and the prior authorization process often happens behind the scenes between your doctor's office and the insurer. By the time you learn about coverage barriers, you may already be facing delays in treatment.

Understanding the facts can save you weeks of frustration and help you get the care you need faster.

Common Myths vs. Facts

Myth 1: "If my doctor prescribes Eylea or Lucentis, UnitedHealthcare will automatically cover it"

Fact: UnitedHealthcare requires prior authorization for both Eylea and Lucentis across commercial, Medicare Advantage, and community plans as of January 2026. Your doctor must submit clinical documentation proving medical necessity before coverage is approved.

Myth 2: "All anti-VEGF injections are covered equally"

Fact: UnitedHealthcare has step therapy requirements that typically mandate trying bevacizumab (Avastin) first due to its lower cost. Eylea and Lucentis are considered non-preferred agents that require documented failure or contraindication to preferred alternatives.

Myth 3: "I can get these injections at any pharmacy"

Fact: While these are physician-administered injections given in your doctor's office, the prior authorization process routes through UnitedHealthcare's specialty pharmacy benefit management. Some plans may have specific network requirements or preferred sites of care that affect coverage.

Myth 4: "Visual acuity doesn't matter for approval"

Fact: While there are no strict visual acuity cutoffs, insurance companies expect documentation of active disease and reasonable expectation of improvement. Your doctor needs to provide OCT imaging showing fluid or other signs of active disease, along with baseline visual acuity measurements.

Myth 5: "Once approved, I'm covered for unlimited injections"

Fact: Prior authorizations typically have duration limits and may require reauthorization. UnitedHealthcare reviews ongoing medical necessity and may require documentation of treatment response, such as improved visual acuity or reduced retinal thickness on OCT.

Myth 6: "If UnitedHealthcare denies coverage, that's the end"

Fact: New Jersey has robust appeal rights. You can pursue internal appeals with UnitedHealthcare, then file for external review through New Jersey's IHCAP program, which has binding authority to overturn insurance denials.

Myth 7: "The appeals process takes forever"

Fact: New Jersey's system is actually quite efficient. Internal UnitedHealthcare appeals must be processed within 30 days for standard cases or 72 hours for expedited reviews. External IHCAP reviews are completed within 45 days for standard cases or 48 hours for urgent situations.

Myth 8: "I need perfect documentation from day one"

Fact: You can strengthen your case during the appeals process. If initially denied for insufficient documentation, you can submit additional clinical records, imaging studies, or literature supporting medical necessity during internal appeals or external review.

What Actually Influences Approval

Understanding UnitedHealthcare's actual decision-making criteria helps you build a stronger case:

Medical Necessity Documentation

  • Diagnosis confirmation: ICD-10 codes for wet AMD (H35.32) or diabetic macular edema (E11.351)
  • OCT imaging: Evidence of subretinal or intraretinal fluid, not just visual acuity scores
  • Baseline measurements: Visual acuity testing and central subfield thickness
  • Treatment history: Documentation of prior therapies tried and their outcomes

Step Therapy Compliance

UnitedHealthcare's ophthalmologic VEGF policy typically requires:

  • Trial of bevacizumab unless contraindicated
  • Documentation of inadequate response or adverse effects
  • Clear clinical rationale for switching to Eylea or Lucentis

Provider Qualifications

  • Prescription from ophthalmologist or retina specialist
  • Documentation of appropriate clinical expertise
  • Proper site of care for administration

When dealing with coverage challenges, Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial reasons and crafting evidence-based rebuttals that align with each payer's specific requirements.

Avoid These Critical Mistakes

1. Waiting Until After Denial to Gather Documentation

The Fix: Work with your doctor's office before initial submission to ensure all required clinical records, imaging, and prior therapy documentation are included.

2. Missing Step Therapy Documentation

The Fix: If you've previously tried bevacizumab, ensure your medical records clearly document the trial, response, and reasons for discontinuation or switching.

3. Submitting Incomplete Prior Authorization Forms

The Fix: Use UnitedHealthcare's Provider Portal to verify current requirements and submit complete applications electronically.

4. Not Requesting Expedited Review When Appropriate

The Fix: If treatment delays could cause serious harm to your vision, ask your doctor to request expedited prior authorization (72-hour turnaround) or expedited appeals.

5. Giving Up After First Denial

The Fix: Remember that you have multiple levels of appeal available, including New Jersey's external review process that has binding authority over insurance decisions.

Your 3-Step Action Plan

Step 1: Verify Current Requirements

Call UnitedHealthcare member services or have your doctor check the Provider Portal to confirm current prior authorization requirements for your specific plan. Requirements can vary between commercial, Medicare Advantage, and community plans.

Step 2: Gather Complete Documentation

Work with your retina specialist to compile:

  • Recent OCT imaging showing active disease
  • Visual acuity measurements
  • Documentation of any prior anti-VEGF treatments
  • Clinical notes supporting medical necessity
  • ICD-10 diagnosis codes

Step 3: Submit and Track

Have your doctor submit the prior authorization electronically through UnitedHealthcare's portal. Standard reviews take up to 7 days, urgent cases 72 hours. Track the status and be prepared to provide additional information if requested.

New Jersey Appeals Process

If your initial prior authorization is denied, New Jersey offers strong consumer protections:

Internal Appeals with UnitedHealthcare

  • Deadline: 180 days from denial notice
  • Timeline: 30 days for standard appeals, 72 hours for expedited
  • Submission: Via UHC Provider Portal or member portal

External Review Through IHCAP

If internal appeals are unsuccessful, you can file for external review through New Jersey's Independent Health Care Appeals Program:

  • Administrator: Maximus Federal Services
  • Deadline: 180 days from final internal denial
  • Timeline: 45 days for standard review, 48 hours for expedited
  • Cost: Free to you (insurer pays all costs)
  • Authority: Binding decision that UnitedHealthcare must follow

The external review is conducted by independent physicians with appropriate specialty expertise who can overturn UnitedHealthcare's denial if they find the treatment is medically necessary.

For complex cases involving multiple denial reasons, Counterforce Health helps patients and providers craft targeted appeals that address each specific coverage barrier with appropriate clinical evidence and policy citations.

FAQ

How long does UnitedHealthcare prior authorization take for Eylea or Lucentis in New Jersey? Standard prior authorization reviews take up to 7 calendar days. Urgent cases (where delay could cause serious harm) are processed within 72 hours.

What if these drugs aren't on my UnitedHealthcare formulary? Even non-formulary drugs can be covered through prior authorization or formulary exceptions if medically necessary and preferred alternatives are inappropriate.

Can I request an expedited appeal if my vision is worsening? Yes, if treatment delays could cause serious deterioration in your vision, you can request expedited internal appeals (72 hours) and expedited external review (48 hours) in New Jersey.

Does step therapy apply if I tried bevacizumab outside New Jersey? Yes, documented trials of step therapy drugs from other states should count, provided you have medical records showing the trial and outcome.

What happens if UnitedHealthcare approves but limits injection frequency? You can appeal quantity limits separately, providing clinical evidence that more frequent dosing is medically necessary based on your response and clinical guidelines.

Can my doctor do a peer-to-peer review before formal appeal? Yes, UnitedHealthcare offers peer-to-peer consultations where your doctor can discuss the case directly with a UHC medical director within 24 hours of denial for outpatient cases.

Resources

UnitedHealthcare Resources

New Jersey State Resources

  • IHCAP Information
  • NJ Department of Banking and Insurance Consumer Hotline: 1-800-446-7467
  • IHCAP Hotline: 1-888-393-1062

Clinical Guidelines

  • OCT in Ophthalmology
  • FDA prescribing information for Eylea and Lucentis (available through manufacturer websites)

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on your specific insurance plan and clinical circumstances. Always consult with your healthcare provider and insurance company for personalized guidance. For additional help with complex coverage issues, consider consulting with advocacy services that specialize in insurance appeals.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.